ArticleBioinformatics (Oxford, England)2019
Drug repositioning based on bounded nuclear norm regularization.
Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- KGTC-DDA:Drug-disease association prediction based on parallel graph isomorphism and transformer networks with cross-attention.Biochemistry and biophysics reports · 2026Article
- DRQuantum: a drug repurposing method by quantum walks on a multi-layered heterogeneous network.Scientific reports · 2026Article
- A Graph Neural Network Framework with Equivariance and Heterogeneity for Drug Repositioning.Interdisciplinary sciences, computational life sciences · 2026Article
- A dual-branch graph neural network architecture for drug-target binding affinity prediction.Scientific reports · 2026Article
- From General-Purpose to Disease-Specific Features: Aligning LLM Embeddings on a Disease-Specific Biomedical Knowledge Graph for Drug Repurposing.bioRxiv : the preprint server for biology · 2026Article
- Multi-DDA: drug-disease association prediction using a hybrid graph convolutional network with multi-modal drug representations.Bioinformatics advances · 2026Article
- RWRGDR: Random Walk and GraphSAGE-based Framework for Enhanced Drug Repositioning.Current drug targets · 2026Article
- Benchmarking heterogeneous network-based methods for drug repurposing.NPJ systems biology and applications · 2025Article
- A fused deep learning approach to transform drug repositioning.Communications chemistry · 2025Article
- Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms.Bioinformatics (Oxford, England) · 2025Article
- A Novel Drug-Disease Association Prediction Method Based on Deep Non-Negative Matrix Factorization with Local Graph Feature.Interdisciplinary sciences, computational life sciences · 2025Article
- Dual-route embedding-aware graph neural networks for drug repositioning.Briefings in bioinformatics · 2025Article
- Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms.bioRxiv : the preprint server for biology · 2025Article
- Adaptive multi-view learning method for enhanced drug repurposing using chemical-induced transcriptional profiles, knowledge graphs, and large language models.Journal of pharmaceutical analysis · 2025Article
- Biology-Informed Matrix Factorization: An AI-Driven Framework for Enhanced Drug Repositioning.Biology · 2025Article
- Improving drug repositioning accuracy using non-negative matrix tri-factorization.Scientific reports · 2025Article
- Ensemble learning based on matrix completion improves microbe-disease association prediction.Briefings in bioinformatics · 2025Article
- Comprehensive evaluation of pure and hybrid collaborative filtering in drug repurposing.Scientific reports · 2025Article
- DDA-bench: a manually curated database for benchmarking datasets and baseline performance values in predicting drug-disease associations.Frontiers in genetics · 2025Article
- Predicting human miRNA disease association with minimize matrix nuclear norm.Scientific reports · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationComputational drug repositioning is a cost-effective strategy to identify novel indications for existing drugs. Drug repositioning is often modeled as a recommendation system problem. Taking advantage of the known drug-disease associations, the objective of the recommendation system is to identify new treatments by filling out the unknown entries in the drug-disease association matrix, which is known as matrix completion. Underpinned by the fact that common molecular pathways contribute to many different diseases, the recommendation system assumes that the underlying latent factors determining drug-disease associations are highly correlated. In other words, the drug-disease matrix to be completed is low-rank. Accordingly, matrix completion algorithms efficiently constructing low-rank drug-disease matrix approximations consistent with known associations can be of immense help in discovering the novel drug-disease associations.
resultsIn this article, we propose to use a bounded nuclear norm regularization (BNNR) method to complete the drug-disease matrix under the low-rank assumption. Instead of strictly fitting the known elements, BNNR is designed to tolerate the noisy drug-drug and disease-disease similarities by incorporating a regularization term to balance the approximation error and the rank properties. Moreover, additional constraints are incorporated into BNNR to ensure that all predicted matrix entry values are within the specific interval. BNNR is carried out on an adjacency matrix of a heterogeneous drug-disease network, which integrates the drug-drug, drug-disease and disease-disease networks. It not only makes full use of available drugs, diseases and their association information, but also is capable of dealing with cold start naturally. Our computational results show that BNNR yields higher drug-disease association prediction accuracy than the current state-of-the-art methods. The most significant gain is in prediction precision measured as the fraction of the positive predictions that are truly positive, which is particularly useful in drug design practice. Cases studies also confirm the accuracy and reliability of BNNR. AVAILABILITY AND IMPLEMENTATION: The code of BNNR is freely available at https://github.com/BioinformaticsCSU/BNNR. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.